Akston’s lead COVID-19 vaccine candidate, AKS-452, is designed to be more potent and more easily manufactured with a single batch expected to produce hundreds of millions of doses. TRACER Europe will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management.
Akston’s lead COVID-19 vaccine candidate, AKS-452, is designed to be more potent and more easily manufactured with a single batch expected to produce hundreds of millions of doses. TRACER Europe will provide regulatory services, oversight of local manufacturing contractors as well as Phase 1 Study preparation and clinical site management.